DEPAKOTE (divalproex sodium) by AbbVie is tract. First approved in 1983.
Drug data last refreshed Yesterday
DEPAKOTE (divalproex sodium) is an oral delayed-release tablet approved in 1983 for epilepsy, bipolar disorder, and migraine prevention. Its therapeutic mechanism is not fully established but is thought to involve increased brain GABA concentrations. It remains a foundational treatment across three major CNS indications.
Approaching loss of exclusivity with moderate competitive pressure (30/100), signaling transition from growth to defensive strategy and potential team contraction.
tract. The mechanisms by which valproate exerts its therapeutic effects have not been established. It has been suggested that its activity in epilepsy is related to increased brain concentrations of gamma-aminobutyric acid (GABA).
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Divalproex Sodium ER Tablets, 500 mg Under Fed Conditions
Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions
Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD
Bioequivalence Study of Divalproex Sodium Capsules(Sprinkle),125 mg of Dr. Reddy's Under Fasting Condition (Apple Sauce)
Bioequivalence Study of Dr. Reddy's Divalproex Sodium Coated Particles in Capsules, 125 mg, Under Fed Condition
Worked on DEPAKOTE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
DEPAKOTE roles are increasingly focused on defensive market retention, managed care contracting, and patient compliance rather than growth acceleration. Career progression on this product is constrained by LOE and competitive displacement, making it suitable for specialists in legacy-product management or transition planning.